Not Dead.
With a little over 4 million in cash, a small float and a recent acquisition of 11 million shares by Zarrabian Saiid gives one to suspect that you must read in between the lines.
http://www.nasdaq.com/symbol/ljpc/insider-trades
One could say this is a dead shell or one could say this is a ground floor opportunity.
The CEO: Dr Tidmarsh's resume speaks for itself.
http://ljpc.com/about-management.html
George F. Tidmarsh, M.D., Ph.D.
President, Chief Executive Officer and Secretary
Dr. Tidmarsh's 22 years of experience in biotechnology include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla, Dr. Tidmarsh served as the Chief Executive Officer of Solana Therapeutics, Inc. Previously, he served as the Chief Executive Officer of Horizon Pharma, Inc. (NASDAQ: HZNP), a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of conditions such as osteoarthritis and rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) and held senior positions at Coulter Pharmaceutical, Inc. [acquired by GlaxoSmithKline (NYSE: GSK)] and SEQUUS Pharmaceuticals, Inc. [acquired by Johnson & Johnson (NYSE: JNJ)]. While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents. Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology.
What do you think?
z